BioCentury | Aug 11, 2016
Distillery Therapeutics

Therapeutics: ATP-binding cassette sub-family G WHITE member 1 (ABCG1)

...ABCG1 could help treat atherosclerosis. In blood from patients undergoing cardiac catheterization, high levels of ABCG1...
...low Treg numbers. In a mouse model of atherosclerosis, T cell- or Treg-specific knockout of ABCG1...
...Next steps could include identifying and testing inhibitors of ABCG1 in models of atherosclerosis. TARGET/MARKER/PATHWAY: ATP-binding cassette sub-family G WHITE member 1 (ABCG1)...
BioCentury | Sep 10, 2015
Distillery Therapeutics

Therapeutics: ATP-binding cassette sub-family G WHITE member 2 (ABCG2; MXR; BCRP1)

Cancer INDICATION: Brain cancer Cell and mouse studies suggest combining an ABCG2 inhibitor with topotecan could help treat pediatric brain cancer. Levels of ABCG2 were higher in brain cells from pediatric patients with medulloblastoma or...
BioCentury | Mar 26, 2015
Distillery Therapeutics

Therapeutics: ATP-binding cassette sub-family G WHITE member 1 (ABCG1)

...Cancer INDICATION: Cancer In vitro and mouse studies suggest ABCG1 inhibition could help treat cancer. In...
...could help treat cancer. In co-cultures of mouse tumor-associated macrophages and human cancer cell lines, ABCG1...
...steps include identifying an ABCG1 inhibitor that can specifically target human and mouse macrophages. TARGET/MARKER/PATHWAY: ATP-binding cassette sub-family G WHITE member 1 (ABCG1)...
BioCentury | Apr 25, 2013
Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiovascular disease ATP-binding cassette sub-family G member 4 (ABCG4); lyn kinase (LYN); thrombopoietin receptor (CD110; Mpl) Cell culture and mouse studies suggest activating LYN...
BioCentury | Mar 28, 2013
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Hyperuricemia/gout ATP-binding cassette sub-family G WHITE member 2 (ABCG2; MXR; BCRP1) In vitro studies identified small molecule structural correctors of ABCG2 that could help...
BioCentury | Oct 22, 2012
Company News

Cyprotex, Sigma-Aldrich sales and marketing update

Sigma Aldrich's Sigma Life Science business granted Cyprotex a non-exclusive license to offer Sigma's transporter knockout cell lines for ADMET screening and safety studies. The assays were developed using CompoZr Zinc Finger Nuclease (ZFN) technology....
BioCentury | Oct 25, 2010
Company News

Charles River, Transposagen Biopharmaceuticals Inc. sales and marketing update

Charles River received exclusive, worldwide rights to market and distribute Transposagen's TGEM Knockout Rat Models. The models include a rat line with a mutation in the p53 gene and a second line with a mutation...
BioCentury | Sep 9, 2010
Distillery Techniques

Technology: Drug delivery

Approach Summary Licensing status Publication and contact information Drug delivery Improving blood brain barrier (BBB) drug delivery with ATP-binding cassette sub-family G WHITE member 2 (ABCG2; MXR; BCRP1) inhibitors Rodent studies suggest that inhibiting BCRP1...
BioCentury | Jun 17, 2010
Distillery Therapeutics

Indication: Endocrine disease

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes ATP-binding cassette sub-family G WHITE member 1 (ABCG1); peroxisome proliferation-activated receptor-g...
...that increasing levels of ABCG1 could help treat diabetes. Mice with diabetic hyperglycemia had lower Abcg1...
...and higher plasma glucose than nonhyperglycemic mice. In the diabetic mice, a PPARG agonist increased Abcg1...
BioCentury | May 24, 2010
Company News

Optivia Biotechnology Inc. sales and marketing update

Optivia Biotechnology Inc. , Menlo Park, Calif. Business: ADMET Optivia launched its OptiDDI Suite, a polarized mammalian cell assay panel for analyzing seven transporter-related drug-drug interactions (DDI) highlighted by FDA as most clinically relevant to transporter-related...
Items per page:
1 - 10 of 17